Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05562830 · ClinicalTrials.gov registry record · Phase 1
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
A Phase 1 study of Urothelial Carcinoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT05562830 is a Phase 1 study of Urothelial Carcinoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 48 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05562830, a Phase 1 study of Urothelial Carcinoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL MK-3120
- BIOLOGICAL Zilovertamab vedotin
Study Locations (20)
Other
- Rambam Health Care Campus-Oncology ( Site 1501) - Haifa
- Rabin Medical Center-Oncology ( Site 1504) - Petah Tikva
- Sheba Medical Center-ONCOLOGY ( Site 1503) - Ramat Gan
- Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1406) - Naples
California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045) - Orange
- University of California San Francisco ( Site 1044) - San Francisco
Region M. de Santiago
- FALP-UIDO ( Site 1151) - Santiago
- Bradford Hill ( Site 1155) - Santiago
Colorado
- Anschutz Cancer Pavilion ( Site 1017) - Aurora
Illinois
- University of Chicago Medical Center ( Site 1037) - Chicago
Indiana
- Indiana University Melvin and Bren Simon Cancer Center ( Site 1011) - Indianapolis
Missouri
- Siteman Cancer Center ( Site 1038) - St Louis
Ohio
- Cleveland Clinic-Taussig Cancer Center ( Site 1036) - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2028-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05562830
The ClinicalTrials.gov registry entry for NCT05562830 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (80% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05562830 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Region M. de Santiago.
Frequently Asked Questions
What is clinical trial NCT05562830 about?
NCT05562830 is a clinical study titled "A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)". This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease ...
What is the current status of trial NCT05562830?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-11-16. Estimated completion is 2028-06-20.
What conditions does trial NCT05562830 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
What interventions are being tested in trial NCT05562830?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-3120 (BIOLOGICAL), Zilovertamab vedotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT05562830?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05562830 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.